Why the NGS Race is Science's Greatest Story.
NGS has been on a fascinating journey, featuring numerous pioneering players all racing to get their technology to market. A little over 20 years ago, the race began…
Returning from CPhI 2019, in Frankfurt, the words of Eric Langer, President of Bioplan Associates, have stuck with me. Forget the innovation, are biosimilars the real 'workhorse' carrying biopharma to bigger and better things?
A new generation of start-ups are revolutionising cancer diagnosis, detecting disease before patients even show symptoms with liquid biopsy tests. This innovation is rife in the US.
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
Cancer doesn’t always make itself known when it presents itself inside a person. People can live with the disease for a long time and, when symptoms manifest, it can be too late as the cancer has become advanced or has spread.